Table I.
Effects of Bile Salt and Bile Salt Sequestrant on Gastrointestinal Transit and Bowel Function
| A. Effect of NaCDC in Health (mean ± SEM) | ||||
|---|---|---|---|---|
| Placebo N=20 |
CDC 500mg N=20 |
CDC 1000mg N=20 |
P | |
| GE t1/2 (min) | 122.8 ± 6.1 | 126.9 ± 5.3 | 143.0 ± 14.1 | |
| CF 6 (%) | 54.6 ± 6.8 | 49.6 ± 7.0 | 46.0 ± 7.1 | |
| GC 4 | 0.97 ± 0.24 | 0.87 ± 0.18 | 1.27 ± 0.33 | |
| GC 24 | 2.69 ± 0.24 | 2.80 ± 0.27 | 3.76 ± 0.30 | 0.01 |
| GC 48 | 3.76 ± 0.20 | 4.10 ± 0.21 | 4.92 ± 0.05 | <0.0001 |
| AC t1/2 (h) | 14.5 ± 1.7 | 12.1 ± 2.1 | 10.7 ± 1.9 | |
| Stool frequency per day | 1.09 ± 0.13 | 1.50 ± 0.18 | 2.01 ± 0.15 | <0.001 |
| Stool consistency by Bristol Stool Form Scale |
3.51 ± 0.16 | 4.29 ± 0.19 | 4.80 ± 0.15 | <0.0001 |
| Ease of passage (scale1–7) | 3.9 ± 0.03 | 4.1 ± 0.06 | 4.3 ± 0.06 | <0.0001 |
| B. Effects of Colesevelam on Transit, Bowel Function and Mucosal Permeability in Diarrhea-Predominant Irritable Bowel Syndrome (mean ± SEM) | |||
|---|---|---|---|
| Placebo N=12 |
Colesevelam N=12 |
P | |
| GE t1/2 (min) | 119.6 ± 7.69 | 156.1 ± 17.36 | 0.14 |
| CF 6 (%) | 64.5 ± 8.17 | 58.5 ± 8.72 | |
| GC 4 | 0.81 ± 0.19 | 0.42 ± 0.16 | |
| GC 24 | 3.30 ± 0.33 | 2.68 ± 0.32 | 0.18 |
| GC 48 | 4.47 ± 0.20 | 4.65 ± 0.13 | |
| AC t1/2 (h) | 14.9 ± 3.58 | 18.85 ± 2.88 | |
| Stool frequency per day | 2.25 ± 0.34 | 2.14 ± 0.31 | |
| Stool consistency by Bristol Stool Form Scale | 4.57 ± 0.35 | 3.78 ± 0.27 | 0.12 |
| Ease of passage (scale1–7) | 4.39 ± 0.11 | 4.18 ± 0.14 | 0.047 |
| Urinary excretion of mannitol 8–24 hr, mg | 45.8±8.8 | 64.3±13.3 | 0.28 |
| Urinary excretion of lactulose 8–24 hr, mg | 19.9±3.12 | 28.5±5.9 | 0.30 |
| L:M ratio 8–24 hr | 0.49±0.05 | 0.59±0.19 | 0.62 |